Page last updated: 2024-11-05

diethylpropion

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diethylpropion is a sympathomimetic amine that acts as an appetite suppressant. It is a prodrug that is metabolized to phenpropanolamine, which is a norepinephrine and dopamine reuptake inhibitor. Diethylpropion is used to treat obesity, but it has been associated with cardiovascular risks and is not typically recommended as a first-line treatment. It is also used in some countries to treat narcolepsy. The mechanism of action is believed to involve the stimulation of the central nervous system, leading to a decrease in appetite and an increase in metabolism. Diethylpropion has been studied extensively for its effects on appetite, weight loss, and cardiovascular health. Research has shown that it can be effective for short-term weight loss, but it may not be safe or effective for long-term use. It is important to note that diethylpropion is a controlled substance in many countries.'

Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7029
CHEMBL ID1194666
CHEBI ID4530
SCHEMBL ID27330
MeSH IDM0006355

Synonyms (89)

Synonym
AC-13099
propiophenone, 2-(diethylamino)-
1-propanone, 2-(diethylamino)-1-phenyl-
2-(diethylamino)-1-phenylpropan-1-one
adiposon
2-diethylaminopropiophenone
silutin
magrene
fenyl-(1-diethylaminoethyl)keton [czech]
frekentine
amfepramon
amfepramone [inn]
amphepramon
amfepramonum [inn-latin]
dea no. 1610
danylen
einecs 202-019-1
tylinal
nopropiophenone
propiophenone, 2-diethylamino-
amphepramone
tepanil
anfepramona [inn-spanish]
obesitex
cegramine
dobesin
anorex
diethylpropione
hsdb 3059
ur 1423
phepranon
derfon
brn 2804400
neobes
D07444 ,
diethylpropion (ban)
amfepramone (inn)
90-84-6
amfepramone
C06954 ,
diethylpropion
(+/-)-diethylpropion
DB00937
alpha-diethylaminopropiophenone
2-(diethylamino)propiophenone
alpha-benzoyltriethylamine
1-phenyl-2-diethylamino-1-propanone
diethylcathinone
2-(diethylamino)-1-phenyl-1-propanone
amfepramonum
anfepramona
(+-)-diethylpropion
CHEBI:4530 ,
prefamone
regenon
anfepramone
NCGC00167475-01
anfamon
modulor
keramik
tenuate hydrochloride
diethylpropione hydrochloride
parabolin
keramin
j4.327c ,
.alpha.-benzoyltriethylamine
CHEMBL1194666
anferpramon
unii-q94yyu22b8
4-14-00-00144 (beilstein handbook reference)
fenyl-(1-diethylaminoethyl)keton
q94yyu22b8 ,
BRD-A37288617-003-01-4
gtpl7161
amfepramone [hsdb]
diethylpropion [mi]
amfepramone [who-dd]
diethylpropion [vandf]
SCHEMBL27330
XXEPPPIWZFICOJ-UHFFFAOYSA-N
2-(diethylamino)-1-phenyl-1-propanone #
1-phenyl-2-diethylamino-1-propanone hydrochloride
DTXSID6022929 ,
AKOS025401369
diethylpropin
Q2356505
amfepramonum (inn-latin)
dtxcid202929
anfepramona (inn-spanish)

Research Excerpts

Overview

Diethylpropion (DEP) is an amphetamine-like compound used as a coadjutant in the treatment of obesity and which presents toxicological importance as a drug of abuse. Diethyl Propion hydrochloride is an effective adjunct to caloric restriction in therapy of obesity.

ExcerptReferenceRelevance
"Diethylpropion (DEP) is a stimulant drug widely used for weight control in Brazil and other American countries. "( Diethylpropion produces psychostimulant and reward effects.
Bernardes, AM; Garcia-Mijares, M; Silva, MT, 2009
)
3.24
"Diethylpropion (DEP) is an amphetamine-like compound used as a coadjutant in the treatment of obesity and which presents toxicological importance as a drug of abuse. "( Effects of diethylpropion treatment and withdrawal on aorta reactivity, endothelial factors and rat behavior.
Bispo Da Silva, LB; Cordellini, S, 2003
)
2.15
"Diethylpropion hydrochloride is an effective adjunct to caloric restriction in therapy of obesity."( Controlled-release diethylpropion hydrochloride used in a program for weight reduction.
Parsons, WB, 1981
)
1.31
"Diethylpropion is a centrally acting appetite-suppressing drug thought to act primarily through catecholamine pathways in the brain. "( Conditioned place preferences, conditioned locomotion, and behavioral sensitization occur in rats treated with diethylpropion.
Byrne, A; Coutts, RT; Martin-Iverson, MT; Reimer, AR; Urichuk, LJ, 1995
)
1.95
"Diethylpropion (DEP) is an amphetamine-like agent used as an anorectic drug. "( Involvement of dopamine receptors in diethylpropion-induced conditioning place preference.
DeLucia, R; Planeta, CS, 1998
)
2.02
"Diethylpropion hydrochloride is an effective anorexiant at the recommended dose of 25 mg three times a day. "( The objective and timing of drug disposition studies, appendix III. Diethylpropion and its metabolites in the blood plasma of the human after subcutaneous and oral administration.
Goodfriend, MJ; Lang, JF; Lemieux, RE; Wright, GJ, 1975
)
1.93

Effects

ExcerptReferenceRelevance
"Diethylpropion has been available in the market for treating obesity for over 50 years. "( Evaluation of the toxic activity of anorectic diethylpropion in Chinese hamster ovary cells.
da Silva, CJ; Dos Santos, JE; Montaldi, AP; Takahashi, CS, 2015
)
2.12

Actions

ExcerptReferenceRelevance
"Diethylpropion induced an increase in locomotor activity in 60% of the monkeys, which were classified as diethylpropion sensitive, but did not affect locomotion in 40% of the monkeys (diethylpropion insensitive)."( Serotonin1A-receptor antagonism blocks psychostimulant properties of diethylpropion in marmosets (Callithrix penicillata).
Carey, RJ; Huston, JP; Maior, RS; Mello, EL; Müller, CP; Tomaz, C, 2005
)
1.28

Toxicity

ExcerptReferenceRelevance
"Although homeopathic and other alternative products are very popular and are supposed to be safe and harmless they are not free of risks."( Homeopathic products, not as innocent and safe as they seem? A case report.
Biesemans, L; Mortelmans, LJ; Van Rossom, P, 2004
)
0.32
" Dry mouth and insomnia were the most frequent adverse events."( A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
Cercato, C; Halpern, A; Leança, CC; Lopes Filho, AP; Mancini, MC; Roizenblatt, VA; Segal, A, 2009
)
0.57
" It seems to be safe in relation to cardiovascular and psychiatric aspects in a well-selected population."( A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
Cercato, C; Halpern, A; Leança, CC; Lopes Filho, AP; Mancini, MC; Roizenblatt, VA; Segal, A, 2009
)
0.57
" Amfepramone produced only mild adverse events, and they were presented in a greater number than placebo only at 3 months, dry mouth being the the main adverse event."( Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.
del Valle-Laisequilla, CF; Lara-Padilla, E; Pizarro-Castellanos, M; Reyes-García, JG; Rizzoli-Córdoba, A; Rosado-Pérez, J; Soto-Molina, H, 2015
)
0.42
"Preclinical Research & Development Current drugs for obesity treatment have limited efficacy and considerable adverse effects."( Anorectic efficacy and safety of the diethylpropion-topiramate combination in rats.
Cortés-Moreno, GY; Del Valle-Laisequilla, CF; Huerta-Cruz, JC; Lara-Padilla, E; Reyes-García, JG; Roa-Coria, JE; Rocha-González, HI; Zúñiga-Romero, Á, 2018
)
0.75

Bioavailability

ExcerptReferenceRelevance
" The rate of appearance of the compounds in the blood, which reflects their rate of passage through the skin, did not correlated with their rate of absorption into the skin."( Evaluation of the percutaneous absorption and metabolism of some aminopropiophenones.
Beckett, AH; Kyroudis, A; Markantonis, SL, 1986
)
0.27
"The relative bioavailability and pharmacokinetic profile of two amfepramone (diethylpropion) hydrochloride oral preparations were evaluated in 12 normal volunteers using a newly developed gas-liquid chromatographic procedure to monitor the unchanged drug and its two major metabolites in urine, plasma and saliva."( Bioavailability of amfepramone hydrochloride sustained release pellets formulation in healthy subjects.
Beckett, AH; Dangor, CM; Veltman, AM, 1987
)
0.5

Dosage Studied

Fifty cocaine-dependent patients completed a 2-week double-blind, double-dummy, parallel-group comparison of four dosage levels of diethylpropion and placebo. presenting was dramatically increased following dosing with methylphenidate and DiethylPropion.

ExcerptRelevanceReference
" However, there was one notable exception; presenting was dramatically increased following dosing with methylphenidate and diethylpropion."( The effects of several anorexigenics on monkey social behavior.
Bedford, JA; Marquis, DK; Wilson, MC, 1984
)
0.47
" Mice were dosed daily (25 mg/kg po) for 28 days after which time carcass composition was determined."( The contribution of increased thermogenesis to the effect of anorectic drugs on body composition in mice.
Arch, JR, 1981
)
0.26
"Fifty cocaine-dependent patients completed a 2-week double-blind, double-dummy, parallel-group comparison of four dosage levels of diethylpropion and placebo."( Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: a test of the cocaine-agonist hypothesis.
Alim, TN; Deutsch, SI; Lindquist, T; Rosse, RB; Vocci, FJ, 1995
)
1.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
appetite depressantAgent that is used to decrease appetite.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (303)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990228 (75.25)18.7374
1990's22 (7.26)18.2507
2000's24 (7.92)29.6817
2010's26 (8.58)24.3611
2020's3 (0.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.82 (24.57)
Research Supply Index5.93 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index123.91 (26.88)
Search Engine Supply Index2.11 (0.95)

This Compound (67.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials53 (16.36%)5.53%
Reviews26 (8.02%)6.00%
Case Studies25 (7.72%)4.05%
Observational0 (0.00%)0.25%
Other220 (67.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Loss - Louisiana Obese Subjects Study [NCT00115063]Phase 4390 participants (Actual)Interventional2005-07-31Terminated(stopped due to ethical issues of continuing control group without treatment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00115063 (6) [back to overview]Change in Duke Activity Status Index (DASI) Questionnaire Score
NCT00115063 (6) [back to overview]Change in Fasting Plasma Glucose (FPG) in Milligrams Per Deciliter (mg/dL)
NCT00115063 (6) [back to overview]Change in Weight From Baseline in Kilograms (kg)
NCT00115063 (6) [back to overview]Percent Change From Baseline Weight
NCT00115063 (6) [back to overview]Change in Blood Pressure
NCT00115063 (6) [back to overview]Percent Change in Blood Tests- Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Triglycerides and Uric Acid

Change in Duke Activity Status Index (DASI) Questionnaire Score

The DASI was used to access changes in fuctional capacity during the study. The highest score possible is 58.2 and the lowest is 0. The score for each individual question varied depending on the intensity of the activity being evaluated. The higher the score, the more physically active a person is to this set of activities of daily living questions. (NCT00115063)
Timeframe: Baseline, 2 years

Interventionunits on a scale (Mean)
Intensive Medical Intervention-2.1
Access to Weight Loss Informational Website-11.6

[back to top]

Change in Fasting Plasma Glucose (FPG) in Milligrams Per Deciliter (mg/dL)

(NCT00115063)
Timeframe: Baseline, 2 years

Interventionmg/dL (Mean)
Intensive Medical Intervention2.4
Access to Weight Loss Informational Website6.7

[back to top]

Change in Weight From Baseline in Kilograms (kg)

(NCT00115063)
Timeframe: Baseline, 2 years

Interventionkg (Mean)
Intensive Medical Intervention-12.7
Access to Weight Loss Informational Website-0.5

[back to top]

Percent Change From Baseline Weight

(NCT00115063)
Timeframe: Baseline, 2 years

InterventionPercent change (Mean)
Intensive Medical Intervention-9.7
Access to Weight Loss Informational Website-0.4

[back to top]

Change in Blood Pressure

(NCT00115063)
Timeframe: Baseline, 2 years

,
Interventionmillimeter of mercury (mm Hg) (Mean)
systolic blood pressuredystolic blood pressure
Access to Weight Loss Informational Website-8.6-3.2
Intensive Medical Intervention-14.7-4.4

[back to top]

Percent Change in Blood Tests- Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Triglycerides and Uric Acid

(NCT00115063)
Timeframe: Baseline, 2 years

,
InterventionPercent change (Mean)
LDLHDLTriglyceridesUric Acid
Access to Weight Loss Informational Website0.71.5-4.83.1
Intensive Medical Intervention1.87.9-9.2-3.0

[back to top]